Annals of Oncology 13:1329-1330, 2002
© 2002 European Society for Medical Oncology
Editorial |
Dose density and dose intensity: where does CHOP go from here?
Attending Physician, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room H-819, New York, NY 10021, USA (E-mail: portlocc@mskcc.org)
| The first 10% of the full text of this article appears below. |
Non-myeloablative chemotherapy regimens have not been fully explored in the treatment of aggressive non-Hodgkins lymphomas [1]. Two important concepts in the development of new chemotherapy regimens are dose intensity [dose of effective drug administered per unit time (mg/m2/week), calculated per week even when the agent is administered once every 3 weeks as in CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)] and dose density (the frequency of effective drug dose administered) [2, 3]. In aggressive non-Hodgkins lymphomas, myeloablative dose intensity has been successfully established in the autologous stem